Literature DB >> 7340986

Delayed recovery of peripheral blood cell numbers after adjuvant cytotoxic chemotherapy for stage II breast cancer.

M D Goodyear, I R Mackay, I S Russell.   

Abstract

A study was made on the recovery of the bone marrow after adjuvant chemotherapy given to 30 post-mastectomy patients with stage II breast cancer treated with either melphalan or melphalan and methotrexate at 6-weekly intervals for 1 year. Counts of peripheral blood cells were made serially during treatment and then for a further 2 years after stopping chemotherapy. Mean counts for all cell types fell during chemotherapy and recovery was long-delayed. Thus 24 months after chemotherapy, mean counts for total leucocytes and platelets were significantly lower than mean pretreatment counts and counts for a normal female population, and the count for neutrophils was significantly lower than the count before treatment; after 24 months mean counts for lymphocytes were not significantly depressed. Melphalan was assumed to be the agent responsible. Slow haematological recovery after cessation of adjuvant chemotherapy with one particular regimen points to the need for including long-term post-chemotherapy observation of the bone marrow in the assessment of adjuvant chemotherapy programmes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7340986     DOI: 10.1007/bf00258211

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Morphology and enumeration of human blood platelets.

Authors:  G BRECHER; E P CRONKITE
Journal:  J Appl Physiol       Date:  1950-12       Impact factor: 3.531

2.  A 'profile' of immune responsiveness in multiple sclerosis.

Authors:  G R Symington; I R Mackay; S Whittingham; J White; J D Buckley
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

3.  Blood lymphocyte subpopulations in breast cancer patients following radiotherapy.

Authors:  B Petrini; J Wasserman; H Blomgren; E Baral
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

Review 4.  Malignancies associated with immunosuppressive or cytotoxic therapy.

Authors:  I Penn
Journal:  Surgery       Date:  1978-05       Impact factor: 3.982

5.  Blood lymphocyte subpopulations in breast cancer patients following post-operative adjuvant chemotherapy or radiotherapy.

Authors:  B Petrini; J Wasserman; H Blomgren; E Baral; L E Strender; A Wallgren
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

6.  Residual marrow damage from cytotoxic drugs.

Authors:  A Morley
Journal:  Aust N Z J Med       Date:  1980-10

7.  Normal haematological values: sex difference in neutrophil count.

Authors:  B J Bain; J M England
Journal:  Br Med J       Date:  1975-02-08

8.  Changes of granulopoiesis during and after adjuvant chemotherapy of breast cancer.

Authors:  H P Lohrmann; W Schreml; M Lang; M Betzler; T M Fliedner; H Heimpel
Journal:  Br J Haematol       Date:  1978-11       Impact factor: 6.998

9.  L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).

Authors:  B Fisher; A Glass; C Redmond; E R Fisher; B Barton; E Such; P Carbone; S Economou; R Foster; R Frelick; H Lerner; M Levitt; R Margolese; J MacFarlane; D Plotkin; H Shibata; H Volk
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

10.  Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer.

Authors:  H J Lerner
Journal:  Cancer Treat Rep       Date:  1978-08
View more
  2 in total

1.  Preparation and administration of chemotherapy. Haematological consequences for hospital-based nurses.

Authors:  P R Jochimsen; M P Corder; P A Lachenbruch; M E Spaight
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jan-Dec

2.  Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer.

Authors:  I R Mackay; M D Goodyear; C Riglar; J Penschow
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.